Last reviewed · How we verify
Direct acting anticoagulant adverse reaction — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Anxa | ANDEXANET ALFA | Portola Pharamceuticals US | 2018-01-01 | |||
| Andexanet | Andexanet | Portola Pharmaceuticals |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Portola Pharamceuticals US · 1 drug in Direct acting anticoagulant adverse reaction
- Portola Pharmaceuticals · 1 drug in Direct acting anticoagulant adverse reaction
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Direct acting anticoagulant adverse reaction:
- Direct acting anticoagulant adverse reaction treatment updates — RSS
- Direct acting anticoagulant adverse reaction treatment updates — Atom
- Direct acting anticoagulant adverse reaction treatment updates — JSON
Cite this brief
Drug Landscape (2026). Direct acting anticoagulant adverse reaction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/direct-acting-anticoagulant-adverse-reaction. Accessed 2026-06-10.
Related
- Direct acting anticoagulant adverse reaction full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing